BN83495 in Prostate Cancer

NCT00790374 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: BN83495 (Cohort 1)
DRUG: BN83495 (Cohort 2)
DRUG: BN83495 (Cohort 3)

Sponsor

Ipsen